Biomea Fusion, Inc.

NASDAQ: BMEA · Healthcare · Biotechnology

PublicHQ Redwood City, CA · San MateoCIK 0001840439Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 44

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$61.8M

Employees

as of 2026-08-18

Market cap

$97.2M

as of 2026-08-18

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$61.8M-$61.8M2025

Operating income-$83.5M-$83.5M2025

Total assets$58.6M$58.6M2025

Liabilities$29.0M$29.0M2025

Equity$29.6M$29.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Biomea Fusion, Inc.’s financial profile?

Biomea Fusion, Inc. earned -$61.8M in FY2025 net income.

Peers · Healthcare

Polaryx Therapeutics, Inc. Common Stock——Nautilus Biotechnolgy, Inc.——enGene Holdings Inc.——Park Dental Partners, Inc. Common Stock——Hemab Therapeutics Holdings, Inc. Common Stock——Cognition Therapeutics, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEOMichael J. Hitchcock

SectorHealthcare

IndustryBiotechnology

HeadquartersRedwood City, CA

ExchangeNASDAQ: BMEA

Employees40

IPO date2021-04-16

Latest filings

10-Q2026-08-05 8-K2026-08-05 8-K2026-06-11 8-K2026-05-11 10-Q2026-05-11 8-K2026-04-28 DEF 14A2026-04-27 8-K2026-03-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.